Interaction Checker

Alpélisib : interactions médicamenteuses

Alpélisib (Piqray, Vijoice) présente 77 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 32 de niveau majeur, 45 de niveau modéré, 0 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (32)

  • Aprépitantinhibiteur du CYP3A4Majeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Bosentaninducteur du CYP3A4Majeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • CarbamazépineanticonvulsivantMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • CénobamateanticonvulsivantMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • ClobazambenzodiazépineMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • ÉtravirineantirétroviralMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • GriséofulvineantifongiqueMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Lopinavir et ritonavirantirétroviralMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Lorlatinibinducteur du CYP3A4Majeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Mitapivatinducteur du CYP3A4Majeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Mitotaneinducteur du CYP3A4Majeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Modafinilstimulant du SNCMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Nafcillineantibiotique de la famille des pénicillinesMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • NévirapineantirétroviralMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • OxcarbazépineanticonvulsivantMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • PhénobarbitalbarbituriqueMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Phentermine et topiramatestimulant du SNCMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • PrimidoneanticonvulsivantMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • RifabutineantibiotiqueMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • RifampicineantibiotiqueMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • RifapentineantibiotiqueMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • RitonavirantirétroviralMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • Suzétrigineinducteur du CYP3A4Majeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

  • TopiramateanticonvulsivantMajeure

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (notice Alpélisib, Interactions médicamenteuses)

Interactions modérées (45)

  • AzélastineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Azélastine et fluticasoneantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • BéclométasonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • BétaméthasonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Bromphéniramine, pseudoéphédrine et dextrométhorphaneantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • BudésonidecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Budésonide et formotérolcorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • CarbinoxamineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • CétirizineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • ChlorphénamineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • CiclésonidecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • ClémastineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • ClobétasolcorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • CyproheptadineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • DéflazacortcorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • DesloratadineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • DésonidecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • DexchlorphéniramineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • DimenhydrinateantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • DiphénhydramineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • DoxylamineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Doxylamine et pyridoxineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • FexofénadineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • FludrocortisonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • FlunisolidecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • FluocinonidecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • FluticasonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Fluticasone et salmétérolcorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • HalobétasolcorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Hydrocodone et chlorphénamineopioïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • HydrocortisonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • HydroxyzineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • LévocétirizineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • LoratadineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • MéclozineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • MéthylprednisolonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • MométasonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • OlopatadineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Olopatadine et mométasoneantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • PrednisolonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • PrednisonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • ProméthazineantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Prométhazine et codéineopioïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Prométhazine et dextrométhorphaneantihistaminiqueModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • TriamcinolonecorticoïdeModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

Vérifiez Alpélisib avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.